# **DEPARTMENT OF RADIO DIAGNOSIS**

UHID / IP NO	40007082 (13469)	RISNo./Status:	4013904/
Patient Name:	Mr. KISHAN LAL MEENA	Age/Gender:	58 Y/M
Referred By :	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	Ward/Bed No:	OPD
Bill Date/No:	28/10/2023 9:50AM/ OPSCR23- 24/7056	Scan Date :	
Report Date :	28/10/2023 11:30AM	<b>Company Name:</b>	Mediwheel - Arcofemi Health Care Ltd.

## **USG REPORT - ABDOMEN AND PELVIS**

## LIVER:

Is normal in size and uniform echo texture.

No obvious focal lesion seen. No intra hepatic biliary radical dilatation seen.

#### **GALL BLADDER:**

Adequately distended with no obvious wall thickening/pericholecystic fat stranding/fluid. No obvious calculus/polyp/mass seen within.

## **PANCREAS:**

Appears normal in size and shows uniform echo texture. The pancreatic duct is normal. No calcifications are seen.

#### **SPLEEN:**

Appears normal in size and it shows uniform echo texture.

## **RIGHT KIDNEY:**

The shape, size and contour of the right kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

## **LEFT KIDNEY:**

The shape, size and contour of the left kidney appear normal.

Corticomedullary differentiation is maintained. No evidence of pelvicalyceal dilatation.

No calculi seen.

## **URINARY BLADDER:**

Partially distended.

## **PROSTATE:**

Is enlarged in size, measuring approx. 27-29cc in volume.

No focal fluid collections seen.

## **IMPRESSION:**

Prostatomegaly.

**DR. RENU JADIYA** 

Rome Jadys

Consultant - Radiology

MBBS, DNB

# **DEPARTMENT OF CARDIOLOGY**

UHID / IP NO	40007082 (13469)	RISNo./Status:	4013904/
Patient Name:	Mr. KISHAN LAL MEENA	Age/Gender:	58 Y/M
Referred By:	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	Ward/Bed No:	OPD
Bill Date/No:	28/10/2023 9:50AM/ OPSCR23- 24/7056	Scan Date :	
Report Date:	28/10/2023 1:16PM	Company Name:	Final

**REFERRAL REASON: -ROUTINE CHECK-UP** 

## 2D ECHOCARDIOGRAPHY WITH COLOR DOPPLER

#### **M MODE DIMENSIONS: -**

Normal Normal							
11.8	6-12mm			LVIDS	27.2	20-40mm	
46.2		32-	57mm		LVPWS	18.1	mm
11.3		6-1	2mm		AO	37.2	19-37mm
18.6		J	nm		LA	35.4	19-40mm
62-64		>:	55%		RA	-	mm
DOPPLER	R MEA	SUREM	1ENTS &	& CALC	ULATIONS	:	
MORPHOLOGY		VELOC	CITY (m/	's)	GRADIENT		REGURGITATION
				(mmHg)			
NORMAL	E	0.74	e'		-		NIL
	A	0.96	E/e'				
NODALI				<u> </u>			NIII
NORMAL		E	0.	53	-		NIL
	A 0.65						
	1111						
NORMAL	1.15			-		NIL	
NORMAL	0.85					NIL	
					-		
	11.8 46.2 11.3 18.6 62-64 DOPPLER MORPHOLOGY NORMAL	11.8 46.2 11.3 18.6 62-64  DOPPLER MEA MORPHOLOGY  NORMAL  NORMAL  NORMAL	No	Normal	Normal	Normal   LVIDS   46.2   32-57mm   LVPWS   11.3   6-12mm   AO   18.6   mm   LA   62-64   >55%   RA   DOPPLER MEASUREMENTS & CALCULATIONS   MORPHOLOGY   VELOCITY (m/s)   GRAD   (mml   NORMAL   E   0.74   e'   -   A   0.96   E/e'   NORMAL   E   0.53   -   A   0.65   NORMAL   1.15   -   NORMAL   1.15   -   NORMAL   0.85   NORMAL   0.8	Normal   LVIDS   27.2   46.2   32-57mm   LVPWS   18.1   11.3   6-12mm   AO   37.2   18.6   mm   LA   35.4   62-64   >55%   RA   -   DOPPLER MEASUREMENTS & CALCULATIONS:   MORPHOLOGY   VELOCITY (m/s)   GRADIENT (mmHg)   NORMAL   E   0.74   e'   -     A   0.96   E/e'   NORMAL   E   0.53   -     A   0.65   NORMAL   1.15   -     NORMAL   1.15   -     NORMAL   0.85   NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85     NORMAL   0.85   NORMAL   0.85   NORMAL   0.85   NORMAL   0.85   NORMAL     0.85   NORMAL

## **COMMENTS & CONCLUSION: -**

- ALL CARDIAC CHAMBERS ARE NORMAL
- NO RWMA, LVEF 62-64%
- NORMAL LV SYSTOLIC FUNCTION
- GRADE I LV DIASTOLIC DYSFUNCTION
- ALL CARDIAC VALVES ARE NORMAL
- NO EVIDENCE OF CLOT/VEGETATION/PE
- INTACT IVS/IAS

IMPRESSION: - GRADE I LV DIASTOLIC DYSFUNCTION, NORMAL BI VENTRICULAR SYSTOLIC FUNCTIONS

DR SUPRIY JAIN
MBBS, M.D., D.M. (CARDIOLOGY)
INCHARGE & SR. CONSULTANT
INTERVENTIONAL CARDIOLOGY

DR ROOPAM SHARMA
MBBS, PGDCC, FIAE
CONSULTANT & INCHARGE
EMERGENCY, PREVENTIVE CARDIOLOGY
AND WELLNESS CENTRE

Mr. KISHAN LAL MEENA **Patient Name** 

UHID 325855 Age/Gender 58 Yrs/Male **IP/OP Location** O-OPD

**Referred By** Dr. EHCC Consultant

Mobile No. 9773349797 Lab No 558575

**Collection Date** 28/10/2023 11:32AM 28/10/2023 11:33AM **Receiving Date Report Date** 

28/10/2023 12:53PM **Report Status** Final

## **BIOCHEMISTRY**

Test Name	Result	Unit	Biological Ref. Range
			Sample: WHOLE BLOOD EDTA
HBA1C	5.4	%	< 5.7% Nondiabetic 5.7-6.4% Pre-diabetic > 6.4% Indicate Diabetes
			Known Diabetic Patients < 7 % Excellent Control 7 - 8 % Good Control > 8 % Poor Control

Method: - High - performance liquid chromatography HPLC Interpretation:-Monitoring long term glycemic control, testing every 3 to 4 months is generally sufficient. The approximate relationship between HbA1C and mean blood glucose values during the preceding 2 to 3 months.

\*\*End Of Report\*\*

**RESULT ENTERED BY: Mr. MAHENDRA KUMAR** 

Dr. SURENDRA SINGH **CONSULTANT & HOD** MBBS|MD| PATHOLOGY

Dr. ASHISH SHARMA **CONSULTANT & INCHARGE PATHOLOGY** MBBS | MD | PATHOLOGY

Page: 1 Of 1

Patient NameMr. KISHAN LAL MEENALab No558575

 UHID
 325855
 Collection Date
 28/10/2023 11:32AM

 Age/Gender
 58 Yrs/Male
 Receiving Date
 28/10/2023 11:33AM

 ID/OR Location
 O-ORD
 Report Date
 38/10/2023 1:44ABM

 IP/OP Location
 O-OPD
 Report Date
 28/10/2023 1:44PM

Referred ByDr. EHCC ConsultantReport StatusFinal



## **BIOCHEMISTRY**

Test Name Result Unit Biological Ref. Range

Sample: Serum

PSA (TOTAL) 1.12 ng/mL 0.00 - 4.00

Total (Free + complexed) PSA - Prostate specific antigen (tPSA)

9773349797

Mobile No.

Method: ElectroChemiLuminescence ImmunoAssay - ECLIA
Interpretation:-PSA determinations are employed are the monitoring of progress and efficiency of therapy in patients with prostate carcinoma or receiving hormonal therapy.

\*\*End Of Report\*\*

RESULT ENTERED BY : Mr. Ravi

Dr. SURENDRA SINGH CONSULTANT & HOD MBBS|MD| PATHOLOGY Dr. ASHISH SHARMA
CONSULTANT & INCHARGE PATHOLOGY
MBBS|MD| PATHOLOGY

Page: 1 Of 1

Mr. KISHAN LAL MEENA **Patient Name** Lab No 4013904 UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender 58 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 28/10/2023 3:36PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

**Mobile No.** 9079396989

## **BIOCHEMISTRY**

 Test Name
 Result
 Unit
 Biological Ref. Range

 BLOOD GLUCOSE (FASTING)
 Sample: Fl. Plasma

 BLOOD GLUCOSE (FASTING)
 93.2
 mg/dl
 74 - 106

Method: Hexokinase assay.

Interpretation:-Diagnosis and monitoring of treatment in diabetes mellitus and evaluation of carbohydrate metabolism in various diseases.

BLOOD GLUCOSE (PP) Sample: PLASMA

BLOOD GLUCOSE (PP ) 178.6 mg/dl Non – Diabetic: - < 140 mg/dl

Pre – Diabetic: - 140-199 mg/dl Diabetic: - >=200 mg/dl

Method: Hexokinase assay.

THYROID T3 T4 TSH Sample: Serum

Т3	1.420	ng/mL	0.970 - 1.690
T4	6.46	ug/dl	5.53 - 11.00
TSH	6.04 H	μIU/mL	0.40 - 4.05

**RESULT ENTERED BY : NEETU SHARMA** 

Dr. ABHINAY VERMA

Patient Name UHID	Mr. KISHAN LAL MEENA 40007082	Lab No Collection Date	4013904 28/10/2023 10:27AM
Age/Gender	58 Yrs/Male	Receiving Date	28/10/2023 10:32AM
IP/OP Location	O-OPD	Report Date	28/10/2023 3:36PM
Referred By	Dr. ROOPAM SHARMA/ DIWANSHU KHATANA	Report Status	Final
Mobile No.	9079396989		

#### **BIOCHEMISTRY**

T3:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T3 is utilized in thediagnosis of T3-hyperthyroidism the detection of early stages ofhyperthyroidism and for indicating a diagnosis of thyrotoxicosis factitia.

T4:- Method: ElectroChemiLuminescence ImmunoAssay - ECLIA

Interpretation:-The determination of T4 assay employs acompetitive test principle with an antibody specifically directed against T4.

TSH - THYROID STIMULATING HORMONE :- ElectroChemiLuminescenceImmunoAssay - ECLIA

Interpretation: - The determination of TSH serves as theinitial test in thyroid diagnostics. Even very slight changes in the concentrations of the free thyroid hormones bring about much greater opposite changes in the TSH levels.

169.6 H

162.2 H

1.4 L

LFT (LIVER FUNCTION TEST)				Sample: Serum
BILIRUBIN TOTAL	0.77	mg/dl	0.00 - 1.20	
BILIRUBIN INDIRECT	0.59	mg/dl	0.20 - 1.00	
BILIRUBIN DIRECT	0.18	mg/dl	0.00 - 0.40	
SGOT	32.9	U/L	0.0 - 40.0	
SGPT	24.6	U/L	0.0 - 40.0	
TOTAL PROTEIN	8.0	g/dl	6.6 - 8.7	
ALBUMIN	4.7	g/dl	3.5 - 5.2	
GLOBULIN	3.3		1.8 - 3.6	

U/L

Ratio

U/L

41 - 137

1.5 - 2.5

10.0 - 55.0

**RESULT ENTERED BY: NEETU SHARMA** 

ALKALINE PHOSPHATASE

A/G RATIO

**GGTP** 

Dr. ABHINAY VERMA

MBBS | MD | INCHARGE PATHOLOGY

Page: 2 Of 11

Patient NameMr. KISHAN LAL MEENALab No4013904

 UHID
 40007082
 Collection Date
 28/10/2023 10:27AM

 Age/Gender
 58 Yrs/Male
 Receiving Date Report Date
 28/10/2023 10:32AM

 IP/OP Location
 O-OPD
 Report Date
 28/10/2023 3:36PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

**Mobile No.** 9079396989

#### **BIOCHEMISTRY**

**BILIRUBIN TOTAL** :- Method: DPD assay. Interpretation:-Total Bilirubin measurements are used in the diagnosis and treatment of various liver diseases, and of haemolytic and metabolic disorders in adults and newborns. Both obstruction damage to hepatocellular structive.

BILIRUBIN DIRECT :- Method: Diazo method Interpretation:-Determinations of direct bilirubin measure mainly conjugated, water soluble bilirubin.

SGOT - AST :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGOT(AST) measurements are used in the diagnosis and treatment of certain types of liver and heart disease.

SGPT - ALT :- Method: IFCC without pyridoxal phosphate activation. Interpretation:-SGPT(ALT) Ratio Is Used For Differential Diagnosis In Liver Diseases.

TOTAL PROTEINS: - Method: Bivret colorimetric assay. Interpretation:-Total protein measurements are used in the diagnosis and treatment of a variety of liver and kidney diseases and bone marrow as well as metabolic and nutritional disorder.

ALBUMIN: - Method: Colorimetric (BCP) assay. Interpretation:-For Diagnosis and monitoring of liver diseases, e.g. liver cirrhosis, nutritional status.

ALKALINE PHOSPHATASE: - Method: Colorimetric assay according to IFCC. Interpretation:-Elevated serum ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic alcohol abuse. ALT is only slightly elevated in patients who have an uncomplicated myocardial infarction. GGTP-GAMMA GLUTAMYL TRANSPEPTIDASE: - Method: Enzymetic colorimetric assay. Interpretation:-y-glutamyltransferase is used in the diagnosis and monitoring of hepatobiliary disease. Enzymatic activity of GGT is often the only parameter with increased values when testing for such diseases and is one of the most sensitive indicator known.

#### LIPID PROFILE

TOTAL CHOLESTEROL	219		<200 mg/dl :- Desirable 200-240 mg/dl :- Borderline >240 mg/dl :- High
HDL CHOLESTEROL	58.2		High Risk :-<40 mg/dl (Male), <40 mg/dl (Female) Low Risk :->=60 mg/dl (Male), >=60 mg/dl (Female)
LDL CHOLESTEROL	130.4		Optimal :- <100 mg/dl Near or Above Optimal :- 100-129 mg/dl Borderline :- 130-159 mg/dl High :- 160-189 mg/dl Very High :- >190 mg/dl
CHOLESTERO VLDL	16	mg/dl	10 - 50
TRIGLYCERIDES	77.7		Normal :- <150 mg/dl Border Line:- 150 - 199 mg/dl High :- 200 - 499 mg/dl Very high :- > 500 mg/dl
CHOLESTEROL/HDL RATIO	3.8	%	

RESULT ENTERED BY : NEETU SHARMA

Dr. ABHINAY VERMA

**Patient Name** Mr. KISHAN LAL MEENA Lab No 4013904

UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender 58 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 28/10/2023 3:36PM

**Referred By** Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final

Mobile No. 9079396989

#### **BIOCHEMISTRY**

CHOLESTEROL TOTAL :- Method: CHOD-PAP enzymatic colorimetric assay.

interpretation:-The determination of the individual total cholesterol (TC) level is used for screening purposes while for a better risk assessment it is necessary to measure additionally lipid & lipoprotein metabolic disorders. HDL CHOLESTEROL :- Method:-Homogenous enzymetic colorimetric method.

Interpretation: -HDL-cholesterol has a protective against coronary heart disease, while reduced HDL-cholesterol concentrations, particularly in conjunction with elevated triglycerides, increase the cardiovascular disease. LDL CHOLESTEROL :- Method: Homogenous enzymatic colorimetric assay.

Interpretation:-LDL play a key role in causing and influencing the progression of atherosclerosis and in particular coronary sclerosis. The LDL are derived form VLDL rich in TG by the action of various lipolytic enzymes and are synthesized in the liver.
CHOLESTEROL VLDL: - Method: VLDL Calculative

Interpretation: -High triglycerde levels also occur in various diseases of liver, kidneys and pancreas.

DM, nephrosis, liver obstruction.

CHOLESTEROL/HDL RATIO :- Method: Cholesterol/HDL Ratio Calculative

Sample: Serum

25.6	mg/dl	16.60 - 48.50
12.0	mg/dl	6 - 20
0.77	mg/dl	0.60 - 1.10
138.6	mmol/L	136 - 145
4.13	mmol/L	3.50 - 5.50
107.8 H	mmol/L	98 - 107
4.5	mg/dl	3.5 - 7.2
9.72	mg/dl	8.60 - 10.30
	12.0 0.77 138.6 4.13 <b>107.8</b> H	12.0 mg/dl 0.77 mg/dl 138.6 mmol/L 4.13 mmol/L 107.8 H mmol/L 4.5 mg/dl

**RESULT ENTERED BY: NEETU SHARMA** 

Dr. ABHINAY VERMA

**Patient Name** Mr. KISHAN LAL MEENA Lab No 4013904 UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender **Receiving Date** 58 Yrs/Male Report Date O-OPD **IP/OP Location** 28/10/2023 3:36PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

**Mobile No.** 9079396989

CREATININE - SERUM :- Method:-Jaffe method, Interpretation:-To differentiate acute and chronic kidneydisease.

URIC ACID :- Method: Enzymatic colorimetric assay. Interpretation:- Elevated blood concentrations of uricacid are renal diseases with decreased excretion of waste products, starvation, drug abuse and increased alcohol consume.

SODIUM:- Method: ISE electrode. Interpretation:-Decrease: Prolonged vomiting or diarrhea, diminished reabsorption in the kidney and excessive fluid retention. Increase: excessive fluid loss, high salt intake and kidney reabsorption.

POTASSIUM:- Method: ISE electrode. Intrpretation:-Low level: Intake excessive loss formbodydue to diarrhea, vomiting

renal failure, High level: Dehydration, shock severe burns, DKA, renalfailure.

CHLORIDE - SERUM: - Method: ISE electrode. Interpretation: -Decrease: reduced dietary intake, prolonged vomiting and reduced renal reabsorption as well as forms of acidosisand alkalosis.

Increase: dehydration, kidney failure, some form ofacidosis, high dietary or parenteral chloride intake, and salicylate poisoning

UREA:- Method: Urease/GLDH kinetic assay. Interpretation:-Elevations in blood urea nitrogenconcentration are seen in inadequate renal perfusion, shock, diminished bloodvolume, chronic nephritis, nephrosclerosis, tubular necrosis, glomerularnephritis and UTI.

CALCIUM TOTAL: - Method: O-Cresolphthaleine complexone. Interpretation:-Increase in serum PTH or vit-D are usually associated with hypercalcemia. Increased serum calcium levels may also be observed in multiple myeloma and other neoplastic diseases. Hypocalcemia may

beobserved in hypoparathyroidism, nephrosis, and pancreatitis.

**RESULT ENTERED BY : NEETU SHARMA** 

**Patient Name** Mr. KISHAN LAL MEENA Lab No 4013904 UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender **Receiving Date** 58 Yrs/Male **Report Date IP/OP Location** O-OPD 28/10/2023 3:36PM

Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Referred By Report Status** Final

Mobile No. 9079396989

## **BLOOD BANK INVESTIGATION**

**Biological Ref. Range Test Name** Result Unit

**BLOOD GROUPING** "O" Rh Positive

1. Both forward and reverse grouping performed.
2. Test conducted on EDTA whole blood.

**RESULT ENTERED BY: NEETU SHARMA** 

Dr. ABHINAY VERMA

Patient Name Mr. KISHAN LAL MEENA Lab No 4013904 **Collection Date** 28/10/2023 10:27AM UHID 40007082 28/10/2023 10:32AM Age/Gender **Receiving Date** 58 Yrs/Male **Report Date** O-OPD **IP/OP Location** 28/10/2023 3:36PM

Referred By Dr. ROOPAM SHARMA/ DIWANSHU KHATANA Report Status Final

**Mobile No.** 9079396989

## **CLINICAL PATHOLOGY**

Test Name	Result	Unit	Biological Ref. Range	
URINE SUGAR (POST PRANDIAL)				Sample: Urine
URINE SUGAR (POST PRANDIAL)	NEGATIVE		NEGATIVE	
URINE SUGAR (RANDOM)				Sample: Urine
URINE SUGAR (RANDOM)	NEGATIVE		NEGATIVE	
				Sample: Urine
PHYSICAL EXAMINATION				
VOLUME	20	ml		
COLOUR	PALE YELLOW		P YELLOW	
APPEARANCE	CLEAR		CLEAR	
CHEMICAL EXAMINATION				
PH	6.0		5.5 - 7.0	
SPECIFIC GRAVITY	1.015		1.016-1.022	
PROTEIN	NEGATIVE		NEGATIVE	
SUGAR	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
BLOOD	NEGATIVE			
KETONES	NEGATIVE		NEGATIVE	
NITRITE	NEGATIVE		NEGATIVE	
UROBILINOGEN	NEGATIVE		NEGATIVE	
LEUCOCYTE	NEGATIVE		NEGATIVE	
MICROSCOPIC EXAMINATION				
WBCS/HPF	1-2	/hpf	0 - 3	
RBCS/HPF	0-0	/hpf	0 - 2	
EPITHELIAL CELLS/HPF	0-2	/hpf	0 - 1	
CASTS	NIL		NIL	
CRYSTALS	NIL		NIL	

**RESULT ENTERED BY: NEETU SHARMA** 

Dr. ABHINAY VERMA

Mr. KISHAN LAL MEENA **Patient Name** Lab No 4013904 UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender 58 Yrs/Male **Receiving Date Report Date IP/OP Location** O-OPD 28/10/2023 3:36PM

**Referred By** Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final

9079396989 Mobile No.

## **CLINICAL PATHOLOGY**

NIL **BACTERIA** NIL **OHTERS** NIL NIL

Methodology:-

Methodology:Glucose: GOD-POD, Bilirubin: Diazo-Azo-coupling reaction with a diazonium, Ketone: Nitro Pruside reaction, Specific
Gravity: Proton re;ease from ions, Blood: Psuedo-Peroxidase activity oh Haem moiety, pH: Methye Red-Bromothymol Blue
(Double indicator system), Protein: H+ Release by buffer, microscopic & chemical method.
interpretation: Diagnosis of Kidney function, UTI, Presence of Protein, Glucoses, Blood. Vocubulary syntax: Kit insert

**RESULT ENTERED BY: NEETU SHARMA** 

Dr. ABHINAY VERMA

**Patient Name** Mr. KISHAN LAL MEENA Lab No 4013904 UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender 58 Yrs/Male **Receiving Date** Report Date **IP/OP Location** O-OPD 28/10/2023 3:36PM **Referred By** Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final

Mobile No. 9079396989

## **HEMATOLOGY**

Test Name	Result	Unit	Biological Ref. Range
CBC (COMPLETE BLOOD COUNT)			Sample: WHOLE BLOOD EDTA
HAEMOGLOBIN	13.9	g/dl	13.0 - 17.0
PACKED CELL VOLUME(PCV)	42.8	%	40.0 - 50.0
MCV	94.5 H	fl	82 - 92
MCH	30.7	pg	27 - 32
MCHC	32.5	g/dl	32 - 36
RBC COUNT	4.53	millions/cu.mm	4.50 - 5.50
TLC (TOTAL WBC COUNT)	8.63	10^3/ uL	4 - 10
DIFFERENTIAL LEUCOCYTE COUNT			
NEUTROPHILS	63.0	%	40 - 80
LYMPHOCYTE	26.4	%	20 - 40
EOSINOPHILS	2.4	%	1 - 6
MONOCYTES	7.6	%	2 - 10
BASOPHIL	0.6 L	%	1 - 2
PLATELET COUNT	2.27	lakh/cumm	1.500 - 4.500

HAEMOGLOBIN :- Method:-SLS HemoglobinMethodology by Cell Counter.Interpretation:-Low-Anemia, High-Polycythemia.

MCV :- Method:- Calculation bysysmex. MCH: - Method: - Calculation bysysmex.
MCHC: - Method: - Calculation bysysmex.

RBC COUNT :- Method:-Hydrodynamicfocusing.Interpretation:-Low-Anemia, High-Polycythemia.

TLC (TOTAL WBC COUNT) :- Method: -Optical Detectorblock based on Flowcytometry. Interpretation: -High-Leucocytosis, Low-Leucopenia.

NEUTROPHILS :- Method: Optical detectorblock based on Flowcytometry  $\textbf{LYMPHOCYTS} : - \ \texttt{Method:} \ \texttt{Optical} \ \texttt{detectorblock} \ \texttt{based} \ \texttt{on} \ \texttt{Flowcytometry}$ EOSINOPHILS :- Method: Optical detectorblock based on Flowcytometry MONOCYTES :- Method: Optical detectorblock based on Flowcytometry BASOPHIL :- Method: Optical detectorblock based on Flowcytometry

PLATELET COUNT :- Method:-Hydrodynamicfocusing method.Interpretation:-Low-Thrombocytopenia, High-Thrombocytosis.

HCT: Method:- Pulse Height Detection. Interpretation:-Low-Anemia, High-Polycythemia. NOTE: CH- CRITICAL HIGH, CL: CRITICAL LOW, L: LOW, H: HIGH

ESR (ERYTHROCYTE SEDIMENTATION RATE) 15 mm/1st hr 0 - 15

**RESULT ENTERED BY: NEETU SHARMA** 

Dr. ABHINAY VERMA

Patient Name Mr. KISHAN LAL MEENA Lab No 4013904 28/10/2023 10:27AM UHID 40007082 **Collection Date** 28/10/2023 10:32AM Age/Gender **Receiving Date** 58 Yrs/Male **Report Date** O-OPD **IP/OP Location** 28/10/2023 3:36PM Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Referred By Report Status** Final Mobile No. 9079396989

Method:-Modified Westergrens.
Interpretation:-Increased in infections, sepsis, and malignancy.

RESULT ENTERED BY : NEETU SHARMA

Page: 10 Of 11

Mr. KISHAN LAL MEENA **Patient Name** Lab No 4013904 UHID 40007082 **Collection Date** 28/10/2023 10:27AM 28/10/2023 10:32AM Age/Gender **Receiving Date** 58 Yrs/Male **Report Date IP/OP Location** O-OPD 28/10/2023 3:36PM **Referred By** Dr. ROOPAM SHARMA/ DIWANSHU KHATANA **Report Status** Final Mobile No. 9079396989

X Ray

Test Name Result Unit Biological Ref. Range

## X-RAY CHEST P. A. VIEW

Both lung fields are clear.

Both CP angles are clear.

Both hemi-diaphragms are normal in shape and outlines.

Cardiac shadow is within normal limits.

Visualized bony thorax is unremarkable.

Correlate clinically & with other related investigations.

\*\*End Of Report\*\*

RESULT ENTERED BY : NEETU SHARMA

APOORVA JETWANI

Select

Page: 11 Of 11